In addition, the activation of the p53 apoptotic pathway and the increased anticancer drugs sensitivity following miR-122 restoration in HCC [31,85] open the possibility of combined therapeutic strategies to be assessed in preclinical animal models. The gene discussed is TP53; the disease is hepatocellular carcinoma.